Your AI-Trained Oncology Knowledge Connection!
Although tiragolumab plus atezolizumab and chemotherapy missed the primary end point of progression-free survival superiority in the phase 3 SKYSCRAPER-02 trial in patients with extensive-stage small cell lung cancer, it will continue to be evaluated in non–small cell lung cancer.
Based on results of the ZUMA-7 trial, the FDA approved axicabtagene ciloleucel for the treatment of certain patients with large B-cell lymphoma who received chemoimmunotherapy in the frontline setting.
Patients with EGFR-mutated non–small cell lung cancer had an improved survival benefit following treatment with a first-line tyrosine kinase inhibitors plus up-front local radiotherapy.
Patients with human papillomavirus–associated oropharyngeal carcinoma who were given de-escalated doses of radiotherapy saw a better quality of life and favorable outcomes.
The addition of relacorilant to nab-paclitaxel has improved overall survival in patients with recurrent, platinum-resistant ovarian cancer.
In an OncView program, Roy Herbst, MD, PhD, touched on clinical decision-making, monitoring response, and the potential treatment options available for treating non–small cell lung cancer.
Cara Mathews, MD, spoke with CancerNetwork® about research examining dostarlimab vs doxorubicin for patients with mismatch repair–deficient endometrial cancers.
Marina Frimer, MD, spoke about the goals of a phase 2 trial and how it can impact patients with platinum-sensitive recurrent uterine serous carcinoma.
Phillip S. Low, PhD, pioneered development of 177Lu-PSMA-617 for patients with metastatic castration-resistant prostate cancer and spoke about its recent approval.
A significant improvement in progression-free survival was observed in the phase 3 ATHENA-MONO trial with first-line maintenance rucaparib vs placebo in patients with advanced ovarian cancer.
Jun J. Mao, MD, MSCE, reviews how traditional, complementary, and integrative medicine can assist clinicians to better treat patients with cancer all over the world.
In an interview with CancerNetwork® during National Colorectal Cancer Awareness Month, Rachel Pearlman, MS, LGC, highlights recent updates in genetic testing in colorectal cancer and where the field needs to head to provide individuals with better options.
A new drug application for futibatinib has been accepted for priority review in patients with previously treated locally advanced or metastatic cholangiocarcinoma with FGFR2 gene rearrangements.
Patients with cancer are at a higher risk for adverse financial effects compared with those who have not been diagnosed.
Candice Roth, MSN, RN, CENP, spoke about how the electronic treatment pathways have evolved over time.
Ira Winer, MD, PhD, FACOG, spoke about which presentations during The Society of Gynecologic Oncology 2022 Annual Meeting he most enjoyed.
While quality of life did not improve with esophageal-sparing intensity-modulated radiotherapy, patients with stage III/IV non–small cell lung cancer did experience a reduction in symptomatic esophagitis.
A biologics license application for mirvetuximab soravtansine, which demonstrated a clinically meaningful objective response rate, was submitted to the FDA for folate receptor α-high platinum-resistant ovarian cancer that has previously been treated with 1 to 3 lines of systemic treatments.
A real-world study using a voluntary questionnaire found an association between increased pain severity and decreased health-related quality of life for patients with multiple myeloma.
Laurence Albigès, MD, PhD, discusses how immunotherapy combinations have affected the treatment landscape for previously untreated advanced or metastatic renal cell carcinoma.
Brian Slomovitz, MD, Reviews Adjuvant Pembrolizumab and Chemo +/– Radiotherapy in Endometrial Cancer
At SGO 2022, CancerNetwork® spoke with Jyoti Mayadev, MD, about a clinical trial involving immune priming with the PD-L1 inhibitor atezolizumab for patients with locally advanced cervical cancer.
Although clinical trial enrollment declined among patients with lung cancer from 2019 to 2020 during the COVID-19 pandemic, mitigation strategies helped to improve enrollment.
The FDA supported submission of application for approval of zandelisib in follicular lymphoma and other indolent non-Hodgkin lymphomas based on the phase 3 COASTAL trial.
Tanios Bekaii-Saab, MD; Kristen Ciombor, MD, MSCI; and John Strickler, MD, detail key developments and needs in the gastrointestinal cancers landscape.
Experts provide their recommendations for navigating a large and continuously growing treatment landscape, selecting between regimens, and monitoring patients with transplant-ineligible multiple myeloma.
Laurence Albigès, MD, PhD, spotlighted 2-year follow-up data from the phase 3 CheckMate 9ER trial, which looked at nivolumab and cabozantinib in patients with previously untreated advanced or metastatic renal cell carcinoma.
Various healthcare professionals join to discuss the management of a patient diagnosed with HER2-positive breast cancer and consider how to best approach newer treatment strategies through her continuum of care.
Laurence Albigès, MD, PhD, speaks to how patients with treatment-naïve advanced or metastatic renal cell carcinoma can benefit from treatment with nivolumab and ipilimumab.
Patients with prostate cancer who received surgery had the highest rate of treatment-related regret followed by radiotherapy and active surveillance.
